Abstract

This grant proposal is a request for continued partial funding of the Hybridoma Core Facility (HCF) within the Multipurpose Arthritis and Musculoskeletal Disease Center (MAMDC). The primary purpose of the HCF is to produce monoclonal antibodies (Mabs) for members of the MAMDC in as economical a manner as possible. To this end, the HCF will continue to use the procedures which have been successful in the previous granting period to construct mouse and rat hybridomas specific for a variety of protein, carbohydrate, bacterial, viral and cell- associated antigens as outlined in the progress summary. In response to the growing needs of investigators within the MAMDC, the HCF plans to expand its activities to include the generation of T cell lines and clones. In addition to performing fusions, the HCF is actively involved in research projects relating to the development of new techniques for Mab production. Current research interests include the use of recombinant DNA technology in the production of antigen-specific Fab fragments.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Comprehensive Center (P60)
Project #
2P60AR020614-15
Application #
3791947
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294

  Publications

Wu, Jianming; Xie, Fenglong; Qian, Kun et al. (2011) FAS mRNA editing in Human Systemic Lupus Erythematosus. Hum Mutat 32:1268-77
Wang, Feng; Ezell, Scharri J; Zhang, Yong et al. (2010) FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. Invest New Drugs 28:234-41
Wang, Wei; Rayburn, Elizabeth R; Velu, Sadanandan E et al. (2009) In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin Cancer Res 15:3511-8
Wang, Wei; Rayburn, Elizabeth R; Zhao, Yuqing et al. (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
Wang, Wei; Rayburn, Elizabeth R; Hang, Jie et al. (2009) Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 65:306-11
Wang, Wei; Rayburn, Elizabeth R; Hao, Miao et al. (2008) Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 68:809-19
Annis, Douglas S; Gunderson, Kristin A; Mosher, Deane F (2007) Immunochemical analysis of the structure of the signature domains of thrombospondin-1 and thrombospondin-2 in low calcium concentrations. J Biol Chem 282:27067-75
Rayburn, Elizabeth R; Wang, Wei; Zhang, Ruiwen et al. (2007) Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 30:1511-9
Annis, D S; Murphy-Ullrich, J E; Mosher, D F (2006) Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4:459-68
Rayburn, Elizabeth R; Wang, Wei; Zhang, Zhuo et al. (2006) Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 66:1653-63

Showing the most recent 10 out of 145 publications